<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04926155</url>
  </required_header>
  <id_info>
    <org_study_id>2021-FXY-072</org_study_id>
    <nct_id>NCT04926155</nct_id>
  </id_info>
  <brief_title>The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer</brief_title>
  <official_title>A Prospective, Randomized Trial Comparing Metformin Plus Androgen Deprivation Therapy (ADT) and Abiraterone With ADT Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of the addition of metformin to abiraterone&#xD;
      on survival in patients with metastatic castration-resistant prostate cancer (mCRPC). The&#xD;
      half the patients will receive metformin in combination with androgen deprivation therapy&#xD;
      (ADT) and abiraterone, and the other half will receive ADT and abiraterone only.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metastatic castration-resistant prostate cancer (mCRPC) can be treated with ADT plus&#xD;
      abiraterone, ADT plus enzalutamide, ADT plus cabazitaxel, ADT plus docetaxel, ADT plus&#xD;
      olaparib. However, patients have short overall survival after progression to CRPC, although&#xD;
      multiple options are available for mCRPC. Therefore, there is still a need to improve the&#xD;
      therapeutic effect for mCRPC.&#xD;
&#xD;
      Many studies have shown that metabolic syndrome and its components are associated with&#xD;
      increased development and progression of aggressive prostate cancer. Metformin, a common&#xD;
      well-tolerated oral biguanide prescribed for type II diabetes, could be used to decrease the&#xD;
      risk of prostate cancer development and improve the efficacy of treatment. Some studies&#xD;
      reported that metformin could enhance the effectiveness of ADT, and improve recurrence-free&#xD;
      survival, overall survival and cancer-specific survival. A prospective randomized study&#xD;
      reported that metformin potentially lengthen time to CRPC in advanced prostate cancer&#xD;
      patients when combined with ADT especially in those with high risk localized prostate cancer,&#xD;
      clinically node positive and in those with low tumor volume metastatic hormone-sensitive&#xD;
      patients.&#xD;
&#xD;
      After extensive research, there is no published results from prospective randomized trials&#xD;
      evaluating the effect of metformin in combination with ADT and abiraterone among patients&#xD;
      with mCRPC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 23, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival defined from randomization to time till biochemical progression or radiographic progression</measure>
    <time_frame>start of treatment to disease progression, up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival defined from randomization until death due to any reason</measure>
    <time_frame>start of treatment to death, up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression-free survival defined from randomization until radiographic progression</measure>
    <time_frame>start of treatment to radiographic progression, up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events which will be assessed according to NCI-CTC AE 5.0</measure>
    <time_frame>start of treatment to study completion, up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Metformin+ADT+abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will be treatet with metformin plus ADT and abiraterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT+abiraterone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this arm will be treatet with ADT and abiraterone, Abiraterone 1000mg once daily until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.</description>
    <arm_group_label>Metformin+ADT+abiraterone</arm_group_label>
    <other_name>Metformin Hydrochloride Sustained Release Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed and newly diagnosed metastatic hormone-sensitive&#xD;
             adenocarcinoma of the prostate without small cell carcinoma or small cell components.&#xD;
&#xD;
          -  Metastatic adenocarcinoma of the prostate proved by imaging (CT/MRI and/or bone scan).&#xD;
&#xD;
          -  Patients must meet the criteria of CRPC.&#xD;
&#xD;
          -  No prior treatment with chemotherapy and new-generation hormonal therapy including&#xD;
             abiraterone, enzalutamide, apalutamide.&#xD;
&#xD;
          -  Patient must give written informed consent before registration and prior to any trial&#xD;
             related investigations.&#xD;
&#xD;
          -  Age ≥18 years.&#xD;
&#xD;
          -  Serum potassium ≥3.5mmol/ L.&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Ongoing androgen deprivation therapy with drugs or bilateral orchiectomy, and&#xD;
             continuous abiraterone plus prednisone.&#xD;
&#xD;
          -  Patient agrees not to father a child during participation in the trial and during 3&#xD;
             months thereafter.&#xD;
&#xD;
          -  Patient agrees not to participate other interventional trials.&#xD;
&#xD;
          -  Patients are able to swallow study drug as whole tablet.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed diabetes or fasting blood-glucose ≥ 6.1mmol/L, or glycosylated hemoglobin ≥&#xD;
             5.6%.&#xD;
&#xD;
          -  Previous malignancy within 2 years prior to randomization, with the exception of&#xD;
             localized non-melanoma skin cancer and Ta bladder cancer.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to randomization.&#xD;
&#xD;
          -  Treatments with 5a-reductase inhibitors, estrogen, cyproterone acetate, and androgen&#xD;
             within 4 weeks prior to randomization.&#xD;
&#xD;
          -  Known or suspected Central nervous system CNS metastases or active leptomeningeal&#xD;
             disease.&#xD;
&#xD;
          -  Equivalent dosage of &gt;10mg/day prednisone of glucocorticoids for the treatment of&#xD;
             prostate cancer within 4 weeks prior to randomization, or treatment with&#xD;
             glucocorticoids for other reasons.&#xD;
&#xD;
          -  Prior treatment for prostate cancer with flutamide, bicalutamide, ketoconazole,&#xD;
             abiraterone, enzalutamide, apalutamide, docetaxel chemotherapy, or other&#xD;
             interventional drugs for prostate cancer.&#xD;
&#xD;
          -  Neutrophils &lt; 1.5 x 109/L, platelets &lt; 75 x 109/L, hemoglobin &lt; 100 g/L.&#xD;
&#xD;
          -  ALT and AST ≥ 2.5 x ULN, bilirubin ≥ 1.5 x ULN.&#xD;
&#xD;
          -  eGFR&lt;45 ml/min/1.73m2.&#xD;
&#xD;
          -  Allergic to metformin or any ingredients of this tablet.&#xD;
&#xD;
          -  Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Albumin&lt; 30 g/L.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease including:&#xD;
&#xD;
          -  Myocardial infarction within 6 months prior to randomization.&#xD;
&#xD;
          -  Uncontrolled angina within 3 months prior to registration.&#xD;
&#xD;
          -  Congestive heart failure NYHA class III or IV.&#xD;
&#xD;
          -  History of clinically significant ventricular arrhythmias (e.g. ventricular&#xD;
             tachycardia, ventricular fibrillation, torsades de pointes).&#xD;
&#xD;
          -  History of Mobitz II second or third degree heart block without a permanent pacemaker&#xD;
             in place.&#xD;
&#xD;
          -  Systolic pressure&lt; 86 mmHg.&#xD;
&#xD;
          -  Bradycardia, heart rate&lt;45/min.&#xD;
&#xD;
          -  Uncontrolled hypertension as indicated by systolic blood pressure &gt; 170 mmHg OR&#xD;
             diastolic blood pressure &gt; 105 mmHg.&#xD;
&#xD;
          -  Prior treatment with metformin after diagnosis of prostate cancer.&#xD;
&#xD;
          -  Allergic to metformin or any drugs used in this trial.&#xD;
&#xD;
          -  Serious underlying medical condition (at the judgment of the investigator) which could&#xD;
             impair the ability of the patient to participate in the trial (e.g. uncontrolled or&#xD;
             acute severe infection, uncontrolled diabetes).&#xD;
&#xD;
          -  Active or symptomatic viral hepatitis or chronic liver disease. History of pituitary&#xD;
             or adrenal dysfunction.&#xD;
&#xD;
          -  Gastrointestinal disorder affecting absorption.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yonghong Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yonghong Li, M.D.</last_name>
    <phone>86-13711376697</phone>
    <email>liyongh@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhenyu Yang, M.D.</last_name>
    <phone>86-13902290670</phone>
    <email>yangzy@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yonghong Li</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>mCRPC; abiraterone; metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

